Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Latest News 18 Nov 2008 Investor seminar 12 Nov 2008 Confirmation of HGT business day - 18th November 2008 View all news stories >

Events 02 Dec 2008 FT Global Pharmaceutical & Biotechnology Conference 18 Nov 2008 HGT Business Day View all events >